🐕💊 Loyal's Dog Longevity Drugs (LOY-001, LOY-002, LOY-003): The Complete 2026 Guide to Prices, Eligible Breeds, FDA Status and What Your Vet Hasn't Told You Yet
For the first time in history, the FDA has acknowledged that a drug can reasonably be expected to extend a dog's lifespan. The company is Loyal, the biotech founded by Celine Halioua in San Francisco. The lead drug is LOY-002 — a daily beef-flavoured pill for senior dogs of almost any size, now two of three steps away from FDA conditional approval. A second drug, LOY-001, targets the IGF-1 pathway in large and giant breeds — the very mechanism that makes a Great Dane live half as long as a Chihuahua. A third, LOY-003, brings the same benefit in pill form. Loyal CEO Halioua told NBC News she hopes LOY-002 will add roughly one year to a dog's life — equivalent to five "dog years." This guide explains exactly where each drug stands, which dogs qualify, what the realistic cost will be, and the critical questions your vet will need to answer before you start any treatment.
⚡ The Numbers: What We Know Right Now (April 10, 2026)
$150M+ raised: Loyal has raised over $150 million including Series B ($45M) + B-2 round ($22M), backed by Khosla Ventures, Valor Equity Partners, Collaborative Fund — BusinessWire Feb 2025
LOY-002 FDA status: 2 of 3 major requirements for conditional approval completed — Loyal official announcement; TAS (Target Animal Safety) package accepted; RXE (Reasonable Expectation of Effectiveness) accepted Feb 26, 2025
LOY-001 FDA status: RXE accepted November 2023 (BusinessWire) — manufacturing + safety data pending; dvm360 April 2026: "anticipated to be available in 2026, subject to FDA approval"
STAY Study: 1,300 senior dogs enrolled, 70 US vet clinics, first dog dosed December 2023 — largest veterinary clinical trial in history; FDA-concurred design
Projected price: CEO Halioua: "mid-double-digit monthly price" — roughly $40–$90/month depending on drug and dog size; "not something for billionaires' dogs only" — dvm360
Lifespan gain: Halioua to NBC News: "hopeful the drug will extend a dog's lifespan by about one year" — equivalent to ~5 dog years
IGF-1 science: FDA's RXE based on LOY-001's ability to reduce IGF-1 levels; 452-dog observational study across 84 breeds aged 2–18 validated clinical relevance — BusinessWire Nov 2023
🧬 Why Big Dogs Die Young: The IGF-1 Problem Loyal Is Solving
The science behind Loyal's drugs begins with one of the most striking biological paradoxes in veterinary medicine: larger dogs live significantly shorter lives than smaller dogs — sometimes by nearly half. A Great Dane's average lifespan is 8–10 years. A Chihuahua's is 14–18 years. Loyal CEO Celine Halioua (dvm360): "We're looking at rottweilers, Great Danes, Bernese Mountain dogs that, on the extreme, will live nearly half the lifespan that is expected of a chihuahua or a miniature poodle."
The mechanism driving this disparity is IGF-1 (Insulin-like Growth Factor 1) — a hormone linked to cellular growth and metabolism. Large dogs have chronically elevated IGF-1 throughout their adult lives. IGF-1 drives rapid growth — but after physical maturity, continued high IGF-1 accelerates the cellular aging process, promotes cancer risk, and shortens healthspan. Loyal's Brennen McKenzie, Director of Veterinary Medicine (BusinessWire): "At Loyal, we see the short lifespan of big dogs not as inevitable, but as a genetically associated disease caused by historical artificial selection, and therefore amenable to treatment."
LOY-001 and LOY-003 work by correcting the overexpression of IGF-1 and growth hormone in large dogs post-maturity. The observational study validated that lower IGF-1 correlates with better functional outcomes and lower frailty scores in senior dogs. Linda Rhodes, VMD, PhD (BusinessWire Nov 2023): "Developing a treatment that will increase longevity by reducing age-associated disease is a new indication. No drug has ever been approved with such a claim."
🔬 The IGF-1 Connection: Why This Science Is Historically Significant
The IGF-1 / longevity link in dogs is not just a veterinary finding — it mirrors decades of research in human longevity science. Lower IGF-1 is associated with longer lifespan in multiple species. Dogs are genetically more similar to humans than mice (the traditional animal model), making Loyal's work potentially transformative for human aging research. Vinod Khosla, Khosla Ventures (BusinessWire): "Today's announcement marks a first for any longevity drug, and is a big step towards accelerating the path for canines, and ultimately humans." If the FDA approves a drug for canine lifespan extension, it represents the first regulatory recognition anywhere in the world that aging itself can be targeted as a treatable condition.
🐕 Which Breeds Are Eligible for Each Loyal Drug?
Senior Dogs of Nearly All Sizes
Eligible: Dogs ≥ 14 lbs, aged ≥ 10 years
Form: Daily beef-flavoured pill (oral)
Target: Metabolic dysfunction; reduces frailty; supports healthy aging
STAY Study: 1,300 dogs enrolled at 70 US clinics (largest vet trial in history)
Price estimate: Mid-double-digit monthly (~$40–$90/month)
2 of 3 FDA conditional approval requirements metLarge and Giant Breed Dogs
Eligible: Dogs ≥ 40 lbs, aged ≥ 7 years
Form: Veterinarian-administered injection every 3–6 months
Target: IGF-1 reduction; corrects growth-related accelerated aging
FDA milestone: RXE accepted November 2023
Next step: Manufacturing + safety data submission; anticipated 2026 availability
RXE accepted — manufacturing/safety pendingLarge and Giant Breed Dogs (Daily Pill Version)
Eligible: Dogs ≥ 60 lbs, aged ≥ 5 years
Form: Daily prescription pill
Target: Same IGF-1 pathway as LOY-001 — easier daily administration
Status: Pre-approval testing; expected to follow LOY-001 in rollout
Note: Designed for long-term daily use vs. periodic injection of LOY-001
Pre-approval testing phase🏆 Which Dog Breeds Need This Drug the Most?
The scientific case for LOY-001/LOY-003 is strongest for large and giant breeds where the IGF-1 lifespan disparity is most severe. Below are the breeds with the highest clinical urgency based on the known lifespan data that Loyal's observational studies addressed:
🐕 Great Dane
🐕 Bernese Mountain Dog
🐕 Rottweiler
🐕 Saint Bernard
🐕 Irish Wolfhound
🐕 Mastiff / English Mastiff
🐕 Labrador Retriever
🐕 German Shepherd
📅 The 2026 FDA Approval Roadmap: What Still Needs to Happen
LOY-001 RXE Accepted — November 2023
FDA Center for Veterinary Medicine formally accepted that Loyal's data provides a Reasonable Expectation of Effectiveness for large-dog lifespan extension. First time the FDA has ever accepted this claim for any longevity drug. (BusinessWire, Nov 27, 2023)
LOY-002 RXE Accepted — February 26, 2025
Second RXE acceptance for Loyal's pipeline. LOY-002 covers senior dogs of nearly all sizes. BusinessWire: "The FDA's acceptance of RXE demonstrates confidence in Loyal's innovative approach." $22M B-2 funding round simultaneously closed. (BusinessWire, Feb 26, 2025)
LOY-002 TAS (Safety Package) Accepted — 2025
Loyal announced completion of the Target Animal Safety package for LOY-002 — the second of three major requirements for conditional approval. loyalfordogs.com: "We've completed two of three major requirements for conditional approval." This is a significant safety milestone.
Current Status (April 2026): STAY Study Ongoing + LOY-001 Manufacturing/Safety Pending
STAY Study running at 70 US vet clinics with 1,300 enrolled dogs; LOY-002 one remaining requirement from conditional approval. LOY-001 and LOY-003: manufacturing and safety requirements in progress. dvm360 (April 9, 2026): LOY-001 "anticipated to be available in 2026, subject to FDA approval of Loyal's manufacturing and safety data."
Anticipated: Conditional FDA Approval for LOY-002 + LOY-001
LOY-002: Loyal anticipates completing the third requirement (effectiveness data from STAY Study interim analysis). Conditional approval would allow marketing before full approval, contingent on STAY Study completion. LOY-001: conditional approval for manufacturing/safety expected to be sought by late 2025 per original Loyal timeline. Prescription-only; available through licensed veterinarians across the US.
Full Approval: STAY Study Completion (~4 Years from December 2023)
The STAY Study runs approximately 4 years — completing around 2027. Full FDA approval (vs. conditional) requires the complete STAY Study dataset. dvm360: "Completing enrollment and seeing what the data shows over the next several years is critical." LOY-003 follows LOY-001 in the rollout sequence.
💰 Realistic Cost: What Will Loyal's Drugs Actually Cost Dog Owners?
| Drug | Form | Who Administers | Estimated Monthly Cost | Notes |
|---|---|---|---|---|
| LOY-002 | Daily pill (beef-flavoured) | Owner at home (prescription) | ~$40–$90/month | Most accessible; CEO confirmed "mid-double-digit monthly" price; comparable to many pet insurance premiums |
| LOY-001 | Long-acting injection | Veterinarian every 3–6 months | ~$40–$90/month equivalent + vet visit fees | In-clinic administration adds cost vs. home pill; large dogs may require higher doses |
| LOY-003 | Daily prescription pill | Owner at home | ~$40–$90/month (estimated) | Same IGF-1 target as LOY-001 but daily pill; pricing not yet confirmed by Loyal |
| STAY Study enrollment | Clinical trial participation | Enrolled vet clinics | Potentially at reduced/no cost | Loyal still accepting applicants at select clinics; visit loyalfordogs.com to check eligibility |
💡 Context on the price: Loyal CEO Halioua told dvm360: "This is not something for billionaires' dogs only. We are currently doing the pricing sensitivity work but we're talking to both veterinarians and pet parents. You can safely assume it's going to be in the double digits per month for pet parents when it comes out to market." For comparison, monthly pet insurance premiums for a large breed dog typically run $50–$150/month — and Loyal's drugs may reduce the incidence of expensive age-related conditions that insurance must cover. The drugs are intended to be prescription-only and available through veterinarians, not direct-to-consumer.
🩺 What Your Vet Will Need to Assess Before Starting Treatment
Even once conditionally approved, Loyal's drugs won't be appropriate for every senior dog. Based on the clinical data available, your veterinarian will likely assess:
| Assessment | Why It Matters | What to Expect |
|---|---|---|
| Age and weight eligibility | LOY-002: ≥10 years, ≥14 lbs; LOY-001: ≥7 years, ≥40 lbs; LOY-003: ≥5 years, ≥60 lbs | Basic eligibility check at your senior dog's next visit |
| Baseline bloodwork | IGF-1 levels, kidney/liver function — establishes baseline before intervention; monitors for any drug effect on organ function | Standard senior panel; most clinics do this for dogs 7+ anyway |
| Concurrent medications | IGF-1 modulation may interact with insulin management in diabetic dogs; discuss with your vet if your dog is on any hormonal therapies | Complete medication list at appointment |
| Cancer status | IGF-1 is involved in tumour growth pathways; vet may assess whether a dog with active cancer is an appropriate candidate | Physical exam + any recent diagnostic imaging |
| Cardiovascular health | Large breeds have elevated cardiac risk; vet will assess whether intervention is appropriate for dogs with existing heart disease | Cardiac auscultation; possible echocardiogram for at-risk breeds |
| Overall quality of life | Loyal's goal is extending healthy lifespan, not just years; treatment is most appropriate for dogs who are aging well — not those in end-stage disease | Honest conversation with vet about your dog's current functional status |
⚠️ What We Don't Know Yet: Honest Limitations
⚠️ Important caveats as of April 2026: LOY-002 and LOY-001 have not yet received full FDA approval — only conditional approval is being sought, with full approval contingent on STAY Study completion. Conditional approval allows marketing but means the definitive effectiveness data from the 4-year STAY Study is still being gathered. The drugs have demonstrated a reasonable expectation of effectiveness — not a proven, statistically-confirmed lifespan extension at the population level. The approximately 1-year lifespan extension cited by Halioua is a projection based on mechanism and early data, not the final STAY Study result. Side effects documented so far are mild (injection site reactions, occasional GI upset) but the full long-term safety profile will be established by the STAY Study. If your vet is unfamiliar with Loyal's drugs, that is normal — FDA approval is not yet final. This guide reflects the status as of April 10, 2026.
❓ Frequently Asked Questions
❓ My 9-year-old Labrador weighs 32kg. Does she qualify for LOY-001 right now?
Based on Loyal's published eligibility criteria, LOY-001 targets dogs ≥40 lbs (18kg) aged ≥7 years. Your Lab at 32kg (70 lbs) and 9 years meets both thresholds for LOY-001. However, LOY-001 is not yet available for prescription — it is pending final FDA conditional approval of manufacturing and safety data. The drug your Lab is most likely to access first is LOY-002, which requires ≥14 lbs and ≥10 years. At 9 years, she is one year below LOY-002's eligibility threshold. Talk to your vet about the STAY Study — your Lab may be eligible to enroll as a participant if a participating clinic is near you (visit loyalfordogs.com to check).
❓ Can I buy LOY-002 or LOY-001 online without a vet prescription?
No. Loyal has confirmed that both drugs will be prescription-only, available exclusively through licensed veterinarians. There is no direct-to-consumer online sale pathway. Any website currently selling "LOY-001" or "LOY-002" is selling an unauthorised product — these drugs are not yet on the commercial market as of April 2026. The appropriate path is: (1) discuss with your vet at your dog's next senior checkup, (2) ask if your vet plans to carry the medication once conditionally approved, or (3) check loyalfordogs.com for STAY Study enrollment near you.
❓ Will pet insurance cover Loyal's longevity drugs?
Almost certainly not initially. Most pet insurance policies cover diagnosis and treatment of illness or injury — not preventive longevity pharmaceuticals. LOY-002 and LOY-001 are explicitly designed as preventive treatments to delay the onset of age-related disease, not to treat an existing diagnosed condition. This means they will likely fall outside standard accident-and-illness insurance coverage. Some wellness add-on plans that cover preventive medications might eventually include Loyal's drugs, but this will require specific policy language changes by insurers. If you use Loyal's drugs, budget for them separately from your insurance costs.
❓ What happens to dogs in the STAY Study if LOY-002 turns out to be ineffective?
The STAY Study is the largest veterinary clinical trial in history — 1,300 dogs, 70 clinics, ~4-year duration, with FDA-concurred design. Dogs in the placebo arm receive standard care. Dogs in the active arm receive LOY-002 (beef-flavoured pill). All enrolled dogs receive enhanced health monitoring throughout the study, which is itself a benefit for aging pets. The FDA's RXE acceptance means the agency believes the data already submitted provides a reasonable basis for expecting effectiveness — the STAY Study is providing the final confirmatory dataset. If interim analyses show unexpected safety concerns, the study protocol includes stopping rules, as required by FDA standards.
Senior Dog Health Log · Vet Record Tracker · Longevity Monitor
Track your senior dog's bloodwork, vet visits, medications, and weight over time — so you're ready the moment Loyal's drugs become available through your vet.
Download Patify FreeAlso on web → patifyapp.com/straypets
Patify — A home for every paw. #PatifyFamily
#LoyalDogDrug2026 #LOY001 #LOY002 #DogLongevityDrug #FDADogLifespan #DogAntAgingDrug #patify
